BR112013024657A2 - antagonistas da s1p como hipotensivos oculares adjuntos - Google Patents

antagonistas da s1p como hipotensivos oculares adjuntos

Info

Publication number
BR112013024657A2
BR112013024657A2 BR112013024657A BR112013024657A BR112013024657A2 BR 112013024657 A2 BR112013024657 A2 BR 112013024657A2 BR 112013024657 A BR112013024657 A BR 112013024657A BR 112013024657 A BR112013024657 A BR 112013024657A BR 112013024657 A2 BR112013024657 A2 BR 112013024657A2
Authority
BR
Brazil
Prior art keywords
antagonists
iop
ocular hypotensive
adjunctive
adjunctive ocular
Prior art date
Application number
BR112013024657A
Other languages
English (en)
Inventor
David F Woodward
Todd M Heidelbauch
W Daniel Stamer
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of BR112013024657A2 publication Critical patent/BR112013024657A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

patente de invenção: antagonistas da s1p como hipotensivos oculares adjuntos a invenção proporciona composições e métodos para reduzir adicionalmente a iop em um paciente que já tenha atingido uma redução máxima de iop usando agentes redutores da iop conhecidos. a atividade de um regime de tratamento hipotensivo ocular pode ser aumentada por adição de um antagonista da s1p, para impedir a inversão mediada pela s1p como resultado do escoamento diminuído do humor aquoso.
BR112013024657A 2011-03-25 2012-03-26 antagonistas da s1p como hipotensivos oculares adjuntos BR112013024657A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161467690P 2011-03-25 2011-03-25
PCT/US2012/030523 WO2012135095A2 (en) 2011-03-25 2012-03-26 S1p antagonists as adjunct ocular hypotensives

Publications (1)

Publication Number Publication Date
BR112013024657A2 true BR112013024657A2 (pt) 2016-12-20

Family

ID=45929630

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013024657A BR112013024657A2 (pt) 2011-03-25 2012-03-26 antagonistas da s1p como hipotensivos oculares adjuntos

Country Status (10)

Country Link
US (1) US20130079290A1 (pt)
EP (1) EP2688593A2 (pt)
JP (1) JP2014508813A (pt)
KR (1) KR20140025412A (pt)
CN (1) CN103561766A (pt)
AU (1) AU2012236850A1 (pt)
BR (1) BR112013024657A2 (pt)
CA (1) CA2831290A1 (pt)
RU (1) RU2013147049A (pt)
WO (1) WO2012135095A2 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103740831B (zh) * 2014-01-13 2015-01-28 宁波海尔施基因科技有限公司 一种指导β-受体阻断药用药的引物组合物、多重基因检测试剂盒及其使用方法
US20210038502A1 (en) 2017-11-08 2021-02-11 INSERM (Institut National de la Santé et de la Recherche Médicale) S1pr2 antagonists for treating diseases involving abnormal immune responses

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG49746A1 (en) * 1992-08-28 1998-06-15 Pharmos Corp Submicron emulsions as ocular drug delivery vehicles
US6646001B2 (en) * 1997-12-19 2003-11-11 Alcon Manufacturing, Ltd. Use of non-steroidal anti-inflammatory agents in combination with prostaglandin FP receptor agonists to treat glaucoma and ocular hypertension
US20020193441A1 (en) * 2001-02-21 2002-12-19 Robertson Stella M. Prostanoid therapies for the treatment of glaucoma
WO2008154470A1 (en) * 2007-06-08 2008-12-18 University Of Connecticut Nhibitor of the receptor activity of the s1p2 receptor for inhibiting pathological angiogenesis in the eye
AU2009244538A1 (en) * 2008-05-08 2009-11-12 Allergan, Inc. Therapeutically useful substituted 1, 7-diphenyl-l, 2, 3, 5, 6, 7-hexahydropyrido [ 3, 2, 1-I J ] quinoline compounds
US20090281322A1 (en) * 2008-05-08 2009-11-12 Allergan, Inc. THERAPEUTICALLY USEFUL SUBSTITUTED 1,7-DIPHENYL-1,2,3,5,6,7-HEXAHYDROPYRIDO[3,2,1-Ij]QUINOLINE COMPOUNDS

Also Published As

Publication number Publication date
CA2831290A1 (en) 2012-10-04
EP2688593A2 (en) 2014-01-29
CN103561766A (zh) 2014-02-05
WO2012135095A9 (en) 2013-03-07
JP2014508813A (ja) 2014-04-10
RU2013147049A (ru) 2015-04-27
AU2012236850A1 (en) 2013-10-17
US20130079290A1 (en) 2013-03-28
WO2012135095A3 (en) 2013-01-17
WO2012135095A2 (en) 2012-10-04
KR20140025412A (ko) 2014-03-04

Similar Documents

Publication Publication Date Title
IN2014DN09434A (pt)
BR112013028907A2 (pt) conjugados de proteína-agente ativo e método para preparar os mesmos
EA201490254A1 (ru) Комбинированное лечение гепатита с
BR112014026703A2 (pt) inibidores de dna-pk
BR112015019720A2 (pt) inibidores de (benzil-ciano-metil)-amidas de ácido 2-aza-biciclo[2.2.1]heptano-3-carboxílico substituído da catepsina c
CR20130560A (es) Compuestos de bezotiazol y su uso farmacéutico
CR20170279A (es) Compuestos de carbamoilpiridona policíclicos y su uso farmacéutico
EA201590053A1 (ru) Модуляторы пути системы комплемента и их применение
MX365939B (es) Moduladores del transporte nuclear y usos de los mismos.
BR112015000704A2 (pt) imidazotriazinacarbonitrilas úteis como inibidores de quinase
BR112014006297A2 (pt) inibidores de n-[1-ciano-2-(fenil) etil]-2-azabiciclo [2.2.1] heptano-3-carboxamida de catepsina c, seus usos, e composição farmacêutica
CO7250451A2 (es) Formulación oftálmica y método para mitigar la presbicia
EA201391108A1 (ru) Лечение липодистрофии
MX2016000364A (es) Metodos para tratar o prevenir afecciones oftalmologicas.
MX2011009847A (es) Agentes antihelminticos y su uso.
MX345042B (es) Composiciones y métodos para tratamiento no quirúrgico de ptosis.
EA201400002A1 (ru) Способы лечения заболеваний сетчатки
BR112014010376A2 (pt) medicamento para o tratamento de doença do olho anterior que compreende rebamipida e um agente de retenção de lágrima
TR201900863T4 (tr) Beta-klorosiklopentanların hidrofilik ester ön ilaçlarının kullanılmasıyla merkezi korneal kalınlaşmanın azaltılması.
RS53783B1 (en) INHALATION MEDICINAL PRODUCTS INCLUDING TIOTROPIUM
CY1117458T1 (el) Αγωνιστες αδενοσινης α1 για τη θεραπευτικη αντιμετωπιση του γλαυκωματος και της οφθαλμικης υπερτασης
BR112014000634A2 (pt) métodos para tratamento de incontinência associada com atividade sexual
BR112014010729A2 (pt) métodos para tratamento de ataques de gota
EA201490199A1 (ru) Терапевтические способы
MD20140004A2 (en) Deuterated 1-piperazino-3-phenyl-indanes for treatment of schizophrenia

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal acc. article 33 of ipl - extension of time limit for request of examination expired